Table 2.
Pre-and post-NCR expression of PD-L1 in all 29 cases, using two different antibodies for staining
| Expression of PD-L1 before and after NCR | ||||
|---|---|---|---|---|
| Factor | Antibody E1L3N | Antibody 5H1 | ||
| (n = 29) | (%) | (n = 29) | (%) | |
| PD-L1 expression tumor pre-NCR | ||||
| 0 | 29 | (100) | 29 | (100) |
| 1 | 0 | (0) | 0 | (0) |
| 2 | 0 | (0) | 0 | (0) |
| 3 | 0 | (0) | 0 | (0) |
| PD-L1 expression stroma pre-NCR | ||||
| 0 | 29 | (100) | 29 | (100) |
| 1 | 0 | (0) | 0 | (0) |
| 2 | 0 | (0) | 0 | (0) |
| 3 | 0 | (0) | 0 | (0) |
| PD-L1 expression tumor post-NCR | ||||
| 0 | 29 | (100) | 29 | (100) |
| 1 | 0 | (0) | 0 | (0) |
| 2 | 0 | (0) | 0 | (0) |
| 3 | 0 | (0) | 0 | (0) |
| PD-L1 expression stroma post-NCR | ||||
| 0 | 24 | (82.76) | 29 | (100) |
| 1 | 5 | (17.24) | 0 | (0) |
| 2 | 0 | (0) | 0 | (0) |
| 3 | 0 | (0) | 0 | (0) |
NCR neoadjuvant chemoradiation